Novartis announced a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting.
According to the 2017 World Malaria Report, there were 216 million cases of malaria in 2016, up from 211 million cases in 2015.
Over the next five years, as part of its commitment, Novartis will invest more than $100 million to advance research and development of next-generation treatments to combat emerging resistance to artemisinin and other currently used antimalarials.
The company will also implement an equitable pricing strategy to maximize patient access in malaria-endemic countries when these new treatments become available. In order to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030, Novartis will further help expand access to pediatric antimalarials and implement healthcare system strengthening programs in 4 sub-Saharan countries.
The R&D investment is meant to advance the Novartis malaria pipeline through 2023 and to complete a comprehensive global clinical trial program for its two novel antimalarial drug candidates.